Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Hims & Hers (HIMS) stock is nosediving after Novo Nordisk (NVO) ended its deal with the company over continued sales of ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Novo Nordisk A/S (NVO) ...

Among them, WW International (WW), formerly known as WeightWatchers, hit a rough patch earlier this year, resulting in WW ...

Digging Into the Bargain Bin Investing in beaten-down stocks can be a savvy strategy for long-term wealth creation, as it ...

Wall Street hits record highs as payrolls surge. Explore healthcare stock movers, obesity drug breakthroughs, AbbVie deals, Centene struggles & ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Novo said the leadership changes were "made in light of the recent market challenges Novo Nordisk has been facing ... Mould said that investors must also assess the valuation of Novo stock, which ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

A once-weekly injection of Wegovy® has become available in Singapore, marking the latest step in managing obesity as a ...

Shares climbed approximately 2.4–2.7%, touching highs between $163.93 (£120.58) and $164.37 (£120.90) before pulling back to ...

The ASX fell 0.11pc in trade, with 7 of 11 sectors lower. The resources industry was a silver lining; both gold and iron ore stocks climbed.